0. DOCID:26937 SCORE: 0.00354798978123113
DOCNO: 10940507
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Polymorphism, Genetic
QUALIFIER: genetics
QUALIFIER: genetics
AUTHOR: I Saadat I
AUTHOR: M Saadat M
AFFILIATION: Department of Biology, College of Sciences, Shiraz University, 71454, Shiraz, Iran.
PUBTYPE: Journal Article
JOURNALTITLE: Cancer letters.
COUNTRY: IRELAND
TITLE: The glutathione S-transferase mu polymorphism and susceptibility to acute lymphocytic leukemia.
PUBDATE: 20000901
It has been postulated that the absence of glutathione S-transferase mu (GSTmu), which impairs detoxification of some carcinogens, might predispose some individuals to the development of certain cancers. In the present study, polymorphism of GSTM1 were detected by polymerase chain reaction (PCR) in 38 patients with acute lymphocytic leukemia and 75 normal subjects. The null genotype of GSTM1 was significantly more common among leukemic patients compared with the normal control group (55.3 vs. 32.0%; P<0.025). The absence of the GSTmu enzyme may increase the risk of the development of leukemia.

1. DOCID:29566 SCORE: 0.00310903926299525
DOCNO: 14722609
AUTHOR: Bruce E Kemp BE
AFFILIATION: St. Vincent's Institute of Medical Research, Fitzroy, Victoria, Australia. kemp@ariel.unimelb.edu.au
PUBTYPE: Comment
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: The Journal of clinical investigation.
COUNTRY: United States
TITLE: Bateman domains and adenosine derivatives form a binding contract.
PUBDATE: 20040101
Conserved pairs of CBS sequence motifs (named after cystathionine beta-synthase) found in a wide variety of proteins associate to form Bateman domains. A new study establishes that Bateman domains bind adenosyl compounds and regulate IMP dehydrogenase, CBS, chloride channels, and AMP-activated protein kinase. This discovery reveals how mutations in CBS sequences in these proteins cause hereditary diseases and provides a rich vista of conceptual opportunities for therapies in energy metabolism, obesity, diabetes, cancer, antivirals, and immunosuppression.

2. DOCID:24724 SCORE: 0.00286846808172891
DOCNO: 10860214
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Double Effect
DESCRIPTOR: Ethics
DESCRIPTOR: Ethics, Medical
DESCRIPTOR: Intention
QUALIFIER: legislation & jurisprudence
QUALIFIER: legislation & jurisprudence
AUTHOR: C E Kendall CE
AFFILIATION: St Peter's Hospice, Bristol.
PUBTYPE: Case Reports
PUBTYPE: Journal Article
JOURNALTITLE: Journal of medical ethics.
COUNTRY: ENGLAND
TITLE: At the coalface: medical ethics in practice. A double dose of double effect.
PUBDATE: 20000601
This paper presents a clinically orientated illustration of the doctrine of double effect. The case of an elderly gentleman with advanced cancer is discussed, with particular emphasis on two dilemmas encountered during the terminal phase of his illness. The author describes how the doctrine of double effect was applied to help the team make some complex management decisions.

3. DOCID:27319 SCORE: 0.00265910832642292
DOCNO: 10448183
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: therapy
AUTHOR: J Moppett J
AUTHOR: I Haddadin I
AUTHOR: A B Foot AB
AFFILIATION: The Royal Hospital for Sick Children St Michael's Hill Bristol BS2 8BJ.
PUBTYPE: Journal Article
JOURNALTITLE: Archives of disease in childhood. Fetal and neonatal edition.
COUNTRY: ENGLAND
TITLE: Neonatal neuroblastoma.
PUBDATE: 19990901
Over nine years, 33 children with neonatal neuroblastoma were registered with the UKCCSG (United Kingdom Children's Cancer Study Group). Tumours of all stages were found, but stage 4S disease predominated. Five tumours were detected prenatally by ultrasonography. Treatment varied according to tumour stage. The overall survival of the group was 91%. Ten children have had long term complications as a result of their disease, usually as a result of spinal tumour involvement. The good overall prognosis in this age group is encouraging, but the poor neurological outcome of patients with intraspinal extension is of concern.

4. DOCID:27232 SCORE: 0.00265910785423408
DOCNO: 14659026
OWNER: NLM
STATUS: PubMed-not-MEDLINE
AUTHOR: C P Schultheis CP
AUTHOR: M A Raheem MA
AUTHOR: M C Perry MC
AFFILIATION: University of Missouri/Ellis Fischel Cancer Center, Columbia, Missouri 65203, USA.
PUBTYPE: Journal Article
JOURNALTITLE: Clinical lung cancer.
COUNTRY: United States
TITLE: Second-line chemotherapy for small-cell lung cancer: a review.
PUBDATE: 20011101
Small-cell lung cancer (SCLC) is an aggressive malignancy, and only a minority of patients survive 2 years. Although this cancer is sensitive to both chemotherapy and radiotherapy, the majority of patients relapse, and second-line treatment is an option for many. Currently in the United States, the combination of cisplatin/etoposide is the standard first-line therapy in SCLC. At this time, topotecan is the only Food and Drug Administration-approved chemotherapeutic agent for second-line treatment of SCLC. In this paper, we review studies of second-line chemotherapy for SCLC.

5. DOCID:26694 SCORE: 0.00258279236426558
DOCNO: 11249681
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: pharmacology
QUALIFIER: genetics
QUALIFIER: pharmacology
AUTHOR: G Forni G
AUTHOR: K Boggio K
AFFILIATION: Department of Clinical and Biological Sciences, University of Turin, Ospedale San Luigi Gonzaga, 10043 Orbassano, Italy. forni@pasteur.sluigi.unito.it
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Current opinion in molecular therapeutics.
COUNTRY: England
TITLE: Cytokine gene-engineered vaccines.
PUBDATE: 19990201
Cytokines modulate immune reactivity and have therefore been used to build cancer vaccines. Experimental vaccination of rodents and humans with cytokine-gene engineered tumor cells, fusion proteins between cytokines and tumor antigens, and their DNA have been shown to induce a significant immune memory, even against poorly immunogenic tumors. This immune memory can prevent tumor growth and cure initial metastases, but is poorly effective against established tumors. To date clinical trials have been confined to patients with advanced tumors; so far they suggest that this approach is safe.

6. DOCID:29165 SCORE: 0.00258191354686006
DOCNO: 15854985
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: surgery
QUALIFIER: surgery
QUALIFIER: therapeutic use
QUALIFIER: secondary
AUTHOR: Yoshinobu Ichiki Y
AUTHOR: Masaru Morita M
AUTHOR: Koichi Yano K
AUTHOR: Kenji Sugio K
AUTHOR: Kosei Yasumoto K
AUTHOR: Naofumi Hirose N
AFFILIATION: Second Department of Surgery, University of Occupational and Environmental Health, School of Medicine, Kitakyushu, Japan. y-ichiki@med.uoeh-u.ac.jp
PUBTYPE: Case Reports
PUBTYPE: Journal Article
JOURNALTITLE: The Annals of thoracic surgery.
COUNTRY: Netherlands
TITLE: Iris metastasis of esophageal cancer.
PUBDATE: 20050501
Ocular metastasis in patients with esophageal cancer is quite rare. Several cases have been reported in the literature, but no successful treatments for such metastases have ever been described. We herein report a case of esophageal cancer in which the ocular metastasis was controlled by systemic chemotherapy.

7. DOCID:28991 SCORE: 0.00258191304676728
DOCNO: 16137795
OWNER: NLM
STATUS: In-Data-Review
AUTHOR: Maria Teresa Cocco MT
AUTHOR: Cenzo Congiu C
AUTHOR: Valentina Lilliu V
AUTHOR: Valentina Onnis V
AFFILIATION: Dipartimento di Tossicologia, Università degli Studi di Cagliari, Via Ospedale 72-09124 Cagliari, Italy.
PUBTYPE: Journal Article
JOURNALTITLE: European journal of medicinal chemistry.
COUNTRY: France
TITLE: Synthesis and antiproliferative activity of 2,6-Dibenzylamino-3,5-dicyanopyridines on human cancer cell lines.
PUBDATE: 20051201
A new series of 2,6-dibenzylamino-3,5-dicyanopyridines were synthesized and evaluated for their in vitro anticancer activity toward cell lines of nine different types of human cancer. Some of newly prepared compounds demonstrated remarkable anticancer activity against most of the tested subpanel tumor cell lines.

8. DOCID:19043 SCORE: 0.00257943567755985
DOCNO: 1666957
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: secondary
QUALIFIER: etiology
QUALIFIER: etiology
QUALIFIER: secondary
QUALIFIER: pathology
AUTHOR: S W Park SW
AUTHOR: H J Cho HJ
AUTHOR: W S Choo WS
AUTHOR: K S Chung KS
AUTHOR: H Y Kim HY
AUTHOR: J Y Yoo JY
AUTHOR: J S Kim JS
AUTHOR: H S Shin HS
AFFILIATION: Department of Internal Medicine, College of Medicine, Hallym University, Seoul, Korea.
PUBTYPE: Case Reports
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: The Korean journal of internal medicine.
COUNTRY: KOREA
TITLE: A case of intestinal hemorrhage due to small intestinal metastases from primary lung cancer.
PUBDATE: 19910701
Although intestinal metastases from lung cancer are not rare at postmortem studies, the development of clinically significant symptoms from the gastrointestinal metastases is very unusual. We report a case of small intestinal hemorrhage leading to intestinal perforation secondary to metastases from a large cell carcinoma of the lung in a 31-year-old man along with a review of the literature.

9. DOCID:29441 SCORE: 0.00257479317696229
DOCNO: 12671668
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: methods
QUALIFIER: diagnosis
QUALIFIER: prevention & control
AUTHOR: Michael N Pollak MN
AUTHOR: William D Foulkes WD
AFFILIATION: Programs of Cancer Prevention and Cancer Genetics, McGill University, Montreal, Quebec, Canada H3T 1E2. michael.pollak@mcgill.ca
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Nature reviews. Cancer.
COUNTRY: England
TITLE: Challenges to cancer control by screening.
PUBDATE: 20030401
Population-based screening seems to be a common-sense strategy for controlling cancer, but recent reports have raised controversy concerning the benefits of common screening procedures. Intense efforts to develop and evaluate novel screening technologies are underway; however, effective use of any screening method must take into account any underlying biological considerations. What are these biological issues, and what challenges do clinicians face in screening for common cancers?

10. DOCID:27938 SCORE: 0.00253207957635948
DOCNO: 10431670
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: adverse effects
QUALIFIER: prevention & control
AUTHOR: E M McCarthy EM
AUTHOR: K P Ethridge KP
AUTHOR: R F Wagner RF
AFFILIATION: Department of Dermatology, University of Texas Medical Branch, Galveston 77555-0783, USA.
PUBTYPE: Journal Article
JOURNALTITLE: Cutis; cutaneous medicine for the practitioner.
COUNTRY: UNITED STATES
TITLE: Beach holiday sunburn: the sunscreen paradox and gender differences.
PUBDATE: 19990701
A survey about sunbathing practices was performed on a summer holiday weekend at a Galveston beach. The likelihood of sunburn increased with increasing duration of sun exposure, with 100% of subjects experiencing sunburn after exposure > or = 4.5 hours. Men exhibited a significantly higher frequency of sunburn, employed fewer sun-protective measures, and demonstrated less knowledge concerning sun safety information and skin cancer than women. This information suggests a need for greater educational efforts directed toward changing public attitudes about preventing sunburn, especially those of men, that currently lead to high-risk sunbathing behavior.

11. DOCID:23994 SCORE: 0.00252467834079994
DOCNO: 7735643
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Models, Biological
QUALIFIER: physiology
QUALIFIER: physiology
AUTHOR: N P Reddy NP
AUTHOR: K Patel K
AFFILIATION: Department of Biomedical Engineering, University of Akron, Ohio 44325-0302, USA.
PUBTYPE: Journal Article
JOURNALTITLE: Medical engineering & physics.
COUNTRY: ENGLAND
TITLE: A mathematical model of flow through the terminal lymphatics.
PUBDATE: 19950301
Proper understanding of the mechanisms of fluid absorption and flow through the terminal lymphatics is essential for the control of several pathological conditions such as edema, bedsores and cancer. A mathematical model of the terminal lymphatics was developed using the principles of mechanics. Computer simulation results substantiate the hypothesis that fluid absorption and flow through the terminal lymphatics occur due to suction mechanisms of the adjacent contractile lymphatic segments and due to periodic fluctuations in the interstitial fluid pressure. In addition, the results suggested that increasing the length of a terminal lymphatic vessel beyond a certain limit does not cause further increase in fluid flow into the terminal lymphatic.

12. DOCID:28566 SCORE: 0.00242455394576935
DOCNO: 14730469
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: therapeutic use
QUALIFIER: adverse effects
QUALIFIER: analogs & derivatives
QUALIFIER: therapeutic use
QUALIFIER: chemically induced
QUALIFIER: drug therapy
AUTHOR: R Todd Reilly RT
AFFILIATION: The Johns Hopkins School of Medicine, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street Room 4M08, Baltimore, MD 21231, USA. reilly@jhmi.edu
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: IDrugs : the investigational drugs journal.
COUNTRY: England
TITLE: BNP-7787 (BioNumerik/Baxter Oncology/Grelan).
PUBDATE: 20040101
BioNumerik Pharmacology Inc, Baxter Oncology GmbH (formerly ASTA Medica AG) and Grelan Pharmaceutical Co Ltd are developing BNP-7787 for the potential reduction of toxicity associated with cisplatin and carboplatin treatment in cancer patients.

13. DOCID:22458 SCORE: 0.00239748234730241
DOCNO: 8740561
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: drug therapy
QUALIFIER: therapeutic use
AUTHOR: R J Youle RJ
AFFILIATION: Biochemistry Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892-1414, USA.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Seminars in cancer biology.
COUNTRY: UNITED STATES
TITLE: Immunotoxins for central nervous system malignancy.
PUBDATE: 19960401
Current therapy for primary brain tumors, metastatic brain tumors and leptomeningeal carcinomatosus is inadequate. Monoclonal antibodies and certain biological ligands such as transferrin and epidermal growth factor bind selectively to tumors but in and of themselves have little therapeutic activity. Linking these binding moieties to protein toxins yields new molecules, called immunotoxins, that display enormous cell-type specific toxicity in vitro and could be valuable agents for treatment of CNS cancer. This review discusses our development of immunotoxins to treat brain tumors after systemic, intrathecal and intratumoral injection.

14. DOCID:22570 SCORE: 0.00239312850767678
DOCNO: 7894079
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Cell Transformation, Neoplastic
DESCRIPTOR: Genome, Human
QUALIFIER: analysis
QUALIFIER: genetics
AUTHOR: G Keith G
AUTHOR: G Dirheimer G
AFFILIATION: Institut de Biologie Moléculaire et Cellulaire du Centre National de la Recherche Scientifique, Strasbourg, France.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Current opinion in biotechnology.
COUNTRY: ENGLAND
TITLE: Postlabeling: a sensitive method for studying DNA adducts and their role in carcinogenesis.
PUBDATE: 19950201
The covalent binding of xenobiotics to DNA is an important trigger of the multistage process that leads to carcinogenesis. 32P-postlabeling represents a highly sensitive method for biomonitoring exposure to genotoxic agents and for cancer risk assessment; it is capable of detecting less than one DNA adduct per human genome. Recent improvements to the technique have shown that the resistance of adducted DNA to enzyme digestion may lead to an overestimation of the number of different adducts present in a sample.